{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["avelumab"]],"indication":"thymoma and thymic carcinoma after platinum-based chemotherapy","name":"NCT03076554","nct_id":"NCT03076554","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03076554. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.","label":"Arm 1 Avelumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-03-30","type":"ESTIMATED"},"conditions":["Thymoma","Thymic Carcinoma"],"enrollment":{"count":56,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Avelumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-29","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-03-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety and tolerability of Avelumab based on NCI-CTCAE v4.0","timeFrame":"End of every cycle"},{"measure":"Objective Response Rate (ORR) based on RECIST 1.1 criteria","timeFrame":"Every other cycle"}],"references":[{"citation":"Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015 May;88(2):154-9. doi: 10.1016/j.lungcan.2015.03.003. Epub 2015 Mar 10.","pmid":"25799277","type":"BACKGROUND"},{"citation":"Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429.","pmid":"25402569","type":"BACKGROUND"},{"citation":"Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20.","pmid":"34393061","type":"DERIVED"}],"start_date":{"date":"2017-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","url":"https://clinicaltrials.gov/study/NCT03076554"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03076554"}